A Global Prospective Observational Study of Women With Fabry Disease and Their Infants During Pregnancy and Breastfeeding

Recruiting now

Conditions studied: Fabry Disease

In brief

This is a global prospective observational study of women with Fabry disease and their infants during pregnancy and/or breastfeeding. The study will evaluate outcomes of pregnancy and/or breastfeeding in women and infants exposed to migalastat.

Key facts

Study ID

NCT04252066

Run by

Amicus Therapeutics

People needed

20

Starts

2025-03-18

Expected to finish

2030-02-01

Last updated by the study team

2025-07-08

Who can join

Age: any. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Female patients meeting the following criteria will be eligible for study enrollment:
• Patients with Fabry disease who are pregnant and/or breastfeeding, whether or not they are exposed to migalastat
• Able and willing to provide informed consent or assent, if applicable.
• Able and willing to provide HCP contact information.

You may not qualify if…

• None

Where it is running

• Amicus Therapeutics, Inc. Pregnancy Registry — Philadelphia, Pennsylvania, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.